Richard Schilsky to Camptothecin
This is a "connection" page, showing publications Richard Schilsky has written about Camptothecin.
Connection Strength
0.575
-
Phase I study of topotecan and cisplatin in patients with advanced solid tumors: a cancer and leukemia group B study. J Clin Oncol. 1994 Dec; 12(12):2743-50.
Score: 0.119
-
Dose-finding and pharmacokinetic study to optimize the dosing of irinotecan according to the UGT1A1 genotype of patients with cancer. J Clin Oncol. 2014 Aug 01; 32(22):2328-34.
Score: 0.115
-
A phase I trial of pharmacologic modulation of irinotecan with cyclosporine and phenobarbital. Clin Pharmacol Ther. 2004 Nov; 76(5):490-502.
Score: 0.059
-
Highlights from: 27th congress of the European Society for Medical Oncology. Nice, France. October 18-22, 2002. Clin Colorectal Cancer. 2002 Nov; 2(3):140-5.
Score: 0.051
-
UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity. Pharmacogenomics J. 2002; 2(1):43-7.
Score: 0.048
-
Recommendation for caution with irinotecan, fluorouracil, and leucovorin for colorectal cancer. N Engl J Med. 2001 Jul 12; 345(2):144-5; author reply 146.
Score: 0.047
-
Phase I clinical and pharmacokinetic study of oral 9-aminocamptothecin (NSC-603071). Cancer Chemother Pharmacol. 1998; 42(1):84-7.
Score: 0.037
-
Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial. JAMA. 2017 06 20; 317(23):2392-2401.
Score: 0.035
-
Treatment-related fatal sepsis from topotecan/cisplatin and topotecan/paclitaxel. J Clin Oncol. 1996 Jun; 14(6):1964-5.
Score: 0.033
-
Phase I study of paclitaxel and topotecan in patients with advanced tumors: a cancer and leukemia group B study. J Clin Oncol. 1995 Sep; 13(9):2230-7.
Score: 0.031